Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBPBiotechnology
Healthcare
$2.44 +1.73%
+$0.14 today
- Market cap
- $50.18M
- Beta
- 2.59
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$6.35
52W Low $6.72High $20.56
Volume 0.66M
Average 0.42M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$85.31M
FY 2025 · Annual
Net Income
-$78.54M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 881.71K | 0 | 0 | 0 | 0 |
| Cost of Revenue | 1.64M | 1.49M | 0 | 600K | 0 |
| Gross Profit | (757.53K) | (1.49M) | 0 | (600K) | 0 |
| Gross Margin | -85.9% | — | — | — | — |
| Research & Development | 36.45M | 16.14M | 31.17M | 32.22M | 70.1M |
| Selling, General & Admin | 20.43M | 18.7M | 13.91M | 16.5M | 15.22M |
| Operating Expenses | 55.23M | 33.35M | 45.08M | 48.12M | 85.31M |
| Depreciation & Amortization | 1.64M | 1.49M | 641K | 600K | 233K |
| EBITDA | (42.17M) | (38.73M) | (40.11M) | (37.74M) | (78.3M) |
| EBITDA Margin | -4782.9% | — | — | — | — |
| Operating Income | (55.99M) | (34.84M) | (45.08M) | (48.72M) | (85.31M) |
| Operating Margin | -6350.1% | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 6.31M | 5.53M |
| Interest Expense | 1.83M | 2.13M | 2.92M | 1.87M | 0 |
| Other Income / Expenses | 10.35M | (7.51M) | 474K | 8.51M | 6.77M |
| Income Before Tax | (45.64M) | (42.35M) | (44.6M) | (40.21M) | (78.54M) |
| Pre-Tax Margin | -5176.4% | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (45.55M) | (55.83M) | (44.6M) | (40.21M) | (78.54M) |
| Net Margin | -5166.4% | — | — | — | — |
| EPS (Basic) | (11.13) | (10.15) | (10.31) | (3.68) | (5.90) |
| EPS (Diluted) | (11.13) | (10.15) | (10.31) | (3.68) | (5.90) |
| 4.1M | 4.17M | 4.33M | 10.92M | 13.32M | |
| 4.1M | 4.17M | 4.33M | 10.92M | 13.32M |
CRBP Earnings Waterfall · TTM
NASDAQ:CRBP · Revenue to Net Income
Key Ratios
EPS$-6.60
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-1.4
P/S Ratio0.0
Analysis
$0 of revenue converted into -$84.5M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-6.60, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 10, 2026 | |
| 8-K | Current report | Nov 10, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 2, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 2, 2026 |
How much revenue does CRBP generate?
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported $0.00 of revenue in fiscal 2025.
Is CRBP profitable?
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported -$78.54M of net income.
Continue the stock analysis
Jump to another research area for this company.